View Older Stories View More Recent Stories

Sep 10, 2022 04:13AM Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors
Aug 30, 2022 05:25PM Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates
Aug 30, 2022 05:25PM Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates
Jun 29, 2022 04:05PM Adagene Inc. (ADAG) Announces $10M Share Buyback
Jun 29, 2022 04:05PM Adagene Announces Authorization of Share Repurchase Program up to US$10 Million
Jun 29, 2022 04:05PM Adagene Announces Authorization of Share Repurchase Program up to US$10 Million
May 26, 2022 05:04PM Adagene Inc. (ADAG) Reports Publication of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of ADG126,
May 26, 2022 05:00PM Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
May 26, 2022 05:00PM Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
May 12, 2022 07:00AM Adagene to Participate in Investor Conferences in May and June
May 12, 2022 07:00AM Adagene to Participate in Investor Conferences in May and June
Apr 8, 2022 01:11PM Adagene Inc. (ADAG) Presents Preclical Data Demonstrating First and Best-in-Class Potential for Antibody Candidates at AACR
Apr 8, 2022 01:09PM Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022
Apr 8, 2022 01:09PM Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022
Mar 31, 2022 08:30AM Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update
Mar 31, 2022 08:30AM Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update
Mar 16, 2022 07:00AM Adagene Inc. (ADAG) Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Mar 16, 2022 07:00AM Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Mar 8, 2022 05:28PM Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting
Mar 2, 2022 06:01AM Adagene Inc. (ADAG) Enters SAFEbody Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates
Mar 2, 2022 06:00AM Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates
Feb 8, 2022 07:00AM Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
Feb 2, 2022 04:23PM Adagene Inc. (ADAG) Announces Board and Management Appointments
Feb 2, 2022 04:05PM Adagene Announces Board and Management Appointments to Support Pipeline Growth
Jan 27, 2022 07:00AM Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116
Jan 19, 2022 07:00AM Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.
Jan 13, 2022 04:00AM Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore
Dec 22, 2021 04:06PM Adagene Inc. (ADAG) Achieves Key Milestone in Collaboration with Exelixis for SAFEbody Novel Masked Antibody-Drug Conjugate Candidates
Dec 22, 2021 04:05PM Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked Antibody-Drug Conjugate Candidates
Dec 13, 2021 10:25AM Adagene Inc. (ADAG) Reports Preclinical Data Showcasing Best-in-Class Profiles for ADG153 and ADG152
Dec 13, 2021 10:23AM Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody® and ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody™
Dec 6, 2021 01:49PM Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Cold Tumors Including Pancreatic and Ovarian Cancers for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO
Dec 6, 2021 06:43AM Adagene Inc. (ADAG) Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumors for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO
Dec 6, 2021 06:30AM Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumors for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021
Nov 29, 2021 04:06PM Adagene Inc. (ADAG) Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab
Nov 29, 2021 04:05PM Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab
Nov 22, 2021 05:10PM Adagene Inc. (ADAG) Announces Poster Presentations of Clinical Data for Two Novel Antibody Programs at ESMO Immuno-Oncology Congress 2021
Nov 22, 2021 05:05PM Adagene Announces Poster Presentations of Clinical Data for Two Novel Antibody Programs at ESMO Immuno-Oncology Congress 2021
Nov 9, 2021 04:05PM Adagene to Participate in Upcoming Investor & Industry Conferences in November
Nov 4, 2021 09:24AM Adagene Unveils Preclinical Data from Two Transformative Antibody Programs at Upcoming American Society of Hematology (ASH) Annual Meeting
Oct 27, 2021 07:00AM Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore
Oct 21, 2021 08:00AM Adagene to Participate in the Jefferies Virtual China Biotech Summit
Sep 2, 2021 07:45AM Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
Sep 2, 2021 07:45AM Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
Aug 26, 2021 07:45AM Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates
Aug 26, 2021 07:45AM Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates
Aug 19, 2021 07:03AM Adagene Inc. (ADAG) Announces Collaboration with Merck for Trial of Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)
Aug 19, 2021 07:00AM Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)
Aug 19, 2021 07:00AM Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)
Aug 12, 2021 07:45AM Adagene Inc. (ADAG) Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board
View More Recent Stories View Older Stories